Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006225 · ClinicalTrials.gov registry record · Phase 1
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006225 is a Phase 1 study that has completed, run by Northwestern University.
The verdict
NCT00006225, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. PURPOSE: Randomized phase I/II trial to study the effectiveness of peripheral stem cell transplantation in treating patients who have breast cancer or hematologic cancer.
Interventions
- BIOLOGICAL filgrastim
- BIOLOGICAL recombinant flt3 ligand
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
- BIOLOGICAL recombinant human thrombopoietin
- BIOLOGICAL recombinant interleukin-3
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2004-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006225
The ClinicalTrials.gov registry entry for NCT00006225 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which filgrastim is the first listed.
NCT00006225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006225 about?
NCT00006225 is a clinical study titled "Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. PURPOSE: Randomized phase I/II trial to study the effectiveness of peripheral stem cell transplantation in treating patients who have breast cancer or hemato...
What is the current status of trial NCT00006225?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-11. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00006225?
The interventions under investigation include: filgrastim (BIOLOGICAL), recombinant flt3 ligand (BIOLOGICAL), in vitro-treated peripheral blood stem cell transplantation (PROCEDURE), recombinant human thrombopoietin (BIOLOGICAL), recombinant interleukin-3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006225?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.